An investigation was announced for investors in NASDAQ:VIVO shares over potential breaches of fiduciary duties by certain directors.
Investors who purchased shares of Meridian Bioscience, Inc. (NASDAQ:VIVO) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.
The investigation by a law firm concerns whether certain Meridian Bioscience directors breached their fiduciary duties and caused damage to the company and its shareholders.
On May 17, 2017, the U.S. Food and Drug Administration (“FDA”) issued a warning to Meridian Bioscience, Inc that lead tests conducted by the Company’s subsidiary, Magellan Diagnostics, may be incorrect. According to the FDA, tests performed on blood drawn from a vein has led to “results that are lower than the actual level of lead in the blood.” The FDA has recommended discontinuation of Magellan when testing with venous blood samples.Shares of Meridian Bioscience, Inc. (NASDAQ:VIVO) declined on May 17, 2017 to $13.23 per share.
Those who purchased NASDAQ:VIVO shares have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com